AKT1 and pancreatic neoplasm: Epigallocatechin-3-gallate (EGCG) synergizes with gemcitabine to suppress pancreatic cancer cell growth, migration, and invasion by modulating the expression of EMT markers and inhibiting the Akt pathway [40].